Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 7 | 5 | — | — | 14 |
Triple negative breast neoplasms | D064726 | — | — | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Giredestrant |
INN | giredestrant |
Description | Giredestrant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | estrogens; estrogen antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO |
PDB | — |
CAS-ID | 1953133-47-5 |
RxCUI | — |
ChEMBL ID | CHEMBL4650316 |
ChEBI ID | — |
PubChem CID | 121410806 |
DrugBank | — |
UNII ID | 28P3DU6DB3 (ChemIDplus, GSRS) |